Monoclonal Antibodies in Acute Myeloid Leukemia—Are We There Yet?
Despite recent advances in the treatment of acute myeloid leukemia (AML), relapses remain
high, and long-term survival is poor, emphasizing the need for better treatment options …
high, and long-term survival is poor, emphasizing the need for better treatment options …
Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?
Y Abaza, AT Fathi - Cancer Journal (United States), 2022 - scholars.northwestern.edu
Despite recent advances in the treatment of acute myeloid leukemia (AML), relapses remain
high, and long-term survival is poor, emphasizing the need for better treatment options …
high, and long-term survival is poor, emphasizing the need for better treatment options …
Monoclonal Antibodies in Acute Myeloid Leukemia—Are We There Yet?
Y Abaza, AT Fathi - The Cancer Journal, 2022 - journals.lww.com
Despite recent advances in the treatment of acute myeloid leukemia (AML), relapses remain
high, and long-term survival is poor, emphasizing the need for better treatment options …
high, and long-term survival is poor, emphasizing the need for better treatment options …
Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?
Y Abaza, AT Fathi - Cancer journal (Sudbury, Mass.), 2022 - pubmed.ncbi.nlm.nih.gov
Despite recent advances in the treatment of acute myeloid leukemia (AML), relapses remain
high, and long-term survival is poor, emphasizing the need for better treatment options …
high, and long-term survival is poor, emphasizing the need for better treatment options …
Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?
Y Abaza, AT Fathi - Cancer Journal (Sudbury, Mass.), 2022 - europepmc.org
Despite recent advances in the treatment of acute myeloid leukemia (AML), relapses remain
high, and long-term survival is poor, emphasizing the need for better treatment options …
high, and long-term survival is poor, emphasizing the need for better treatment options …